Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.

Abstract

Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease are presented. Augmentation of brain levels of acetyl-l-carnitine, an endogenous molecule, may help to reverse membrane phospholipid changes in Alzheimer's disease. Neurobiological effects of acetyl-l-carnitine and potential molecular mechanisms of acetyl-l-carnitine activity are reviewed. Clinical trials of acetyl-l-carnitine indicate that it is well-tolerated and may be effective in younger Alzheimer's disease patients and may be an effective adjuvant treatment. Acetyl-l-carnitine may especially benefit those Alzheimer's disease patients with depressive disorders.

• Authors: Jay W Pettegrew, Richard J McClure
• Journal: Expert review of neurotherapeutics (Expert Rev Neurother) Vol. 2 Issue 5 Pg. 647-54 (Sep 2002) ISSN: 1744-8360 [Electronic] England
• PMID: 19810980 (Publication Type: Journal Article)